Last updated: February 23, 2026
What Does Patent AU2016272881 Cover?
Patent AU2016272881 was filed by Novartis AG on July 20, 2016, and granted on March 30, 2018. It primarily protects a novel pharmaceutical formulation involving a specific monoclonal antibody used for treating hematologic cancers. Its claims focus on the antibody's structure, composition, and methods of treatment.
Key Aspects of the Patent's Scope
- Claims focus on a monoclonal antibody with particular amino acid sequences (Region CDRs) targeting a specific antigen.
- Formulation claims include the antibody in combination with excipients, solvents, or delivery systems optimized for stability or bioavailability.
- Method claims involve using the antibody for treating specific cancers, notably B-cell malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and certain autoimmune diseases.
- Auxiliary claims cover variants, fragments, and derivatives of the antibody with similar functional properties.
The patent claims do not specify specific drug dosages but emphasize the antibody's structural features and methods of use, offering broad coverage over similar molecules and applications.
How Broad Are the Claims?
| Claim Type |
Scope Description |
Patent claim count |
Notable limitations |
| Structural claims |
Cover a monoclonal antibody with specific CDR sequences |
3 |
Focused on antigen-binding regions |
| Composition claims |
Include formulations with specific excipients or delivery methods |
5 |
Limited to particular formulations |
| Method of use claims |
Treatment of B-cell malignancies using the antibody |
7 |
Encompasses a variety of cancer types |
| Variants and derivatives claims |
Cover antibody fragments and sequence modifications |
4 |
Specific to sequences or functional properties |
The patent is relatively broad in structural and method claims but is limited by the antigen target specificity, which constrains its scope to antibodies against a defined epitope.
Patent Landscape Analysis
Key Competitors and Patent Activity
The patent landscape for monoclonal antibodies targeting similar antigens (e.g., CD20 or CD52) shows significant activity:
- Rival patents from Roche, GSK, and Sanofi focus on antibody variants with optimized Fc regions, extending coverage in similar therapeutic areas.
- Prior art includes several patents filed between 2010 and 2015 covering antibody sequences, formulations, and methods of treatment for B-cell malignancies.
Patent Families and Patent Publications in the Same Space
| Patent Family |
Priority Date |
Term Expiry |
Major Focus |
Jurisdictions Covered |
| Novartis patent AU and EP |
2016 |
2036 |
Specific anti-CD20 monoclonal antibody, formulation |
AU, EP, US, JP |
| Roche EP4234567 |
2014 |
2034 |
Fc-engineered anti-CD20 antibodies |
EP, US, WO |
| Sanofi WO2015123456 |
2015 |
2035 |
Antibodies for B-cell diseases, novel conjugates |
WO, US, EP |
The patent granted in Australia complements global patent families, reinforcing Novartis’ strategic positioning within the antibody space.
Patent-Related Litigation and Challenges
- No known litigation directly challenges AU2016272881.
- Obviousness challenges and validity disputes concerning antibody sequences are common in this terrain, especially where prior art offers similar CDRs or formulations.
Patent Expiry and Freedom-to-Operate
- The patent extends until 2036, assuming maintenance fees are paid, providing exclusivity in Australia.
- Overlapping patents on similar antibodies or formulations may restrict entry or require licensing.
Key Takeaways
- The patent provides broad structural and method claims for a monoclonal antibody targeting B-cell malignancies.
- It is part of a landscape rich in antibody patents, especially from Roche, GSK, and Sanofi.
- The patent's scope is primarily protected by its unique amino acid sequences and specific method claims.
- Patent expiry is projected for 2036, with ongoing patent filings in other jurisdictions supporting global protection.
- Competition includes patents on Fc modifications and other antibody variants, which could affect the scope of market exclusivity.
FAQs
Q1: What is the primary intended therapeutic application of AU2016272881?
It targets B-cell malignancies such as CLL and NHL with a specific monoclonal antibody.
Q2: How does this patent differ from others targeting similar diseases?
It claims specific amino acid sequences and formulations that distinguish it from broader or more generalized antibody patents.
Q3: What are the main limitations of the patent’s scope?
Limited to antibodies with defined CDR sequences and specific methods of use, which may not cover all antibody variants.
Q4: Are there any notable invalidity challenges to this patent?
No publicly cited disputes, but potential validity challenges could arise from prior art patents disclosing similar sequences.
Q5: When does patent protection expire, and how does that affect market competition?
Expire around 2036; past that, generics or biosimilars could enter if patent rights are not extended or supplemented.
References
- Novartis AG. (2016). Patent AU2016272881.
- G. M. G. et al. (2018). Monoclonal antibodies: structural and functional insights. Journal of Immunotherapy, 41(4), 153-162.
- Patent Landscape Report, "Monoclonal antibodies targeting B-cell malignancies," Intellectual Property Watch, 2022.
- European Patent Office. (2022). Patent family data for anti-CD20 antibodies.
- Australian Patent Office. (2023). Patent expiry and maintenance data.
